The Parkinson’s disease (PD) market is expected to see significant growth in the 7MM*, with the decade starting 2019 seeing an impressive 12.6% compound annual growth rate (CAGR), according to GlobalData. The leading data and analytics company notes that this growth is largely driven by the launch of 17 new pipeline products, which are set to address key unmet needs in the space. However, these will come at a higher cost compared to the currently marketed products, fueling market growth. The market is expected to rise from $3.5bn in 2019 to $11.5bn in 2029.
Sarah Elsayed, Neurology Analyst at GlobalData, comments: “The PD market is highly competitive, featuring many levodopa-combination therapies and adjunctive drug classes that aim to alleviate motor symptoms. However, these current treatment options are primarily symptomatic, off-patent, and not very effective in controlling the motor fluctuations that occur in advanced-stage patients.
“As a result, there are key unmet needs for drugs that have improved efficacy and delivery systems, and that provide disease-modifying benefits. New pipeline agents will aim to address some of these unmet needs and will have higher costs compared to the marketed products, which will fuel the growth of the PD market.”
Leading development strategies in PD across the pipeline mainly include the development of novel targets with potential disease-modifying properties and drug reformulations with innovative delivery systems.
Elsayed continues: “GlobalData anticipates that the most promising pipeline product will be Roche/Prothena’s PRX-002 (prasinezumab), an anti-alpha synuclein monoclonal antibody (mAb) in Phase II development. This drug has shown to potentially halt disease progression in clinical trials. GlobalData forecasts that it will generate global sales of $2.1bn by 2029, achieving the blockbuster status by 2028.”
Several late-stage pipeline agents have innovative systems for delivering levodopa therapy. This includes Intec’s Accordion Pill (levodopa/carbidopa) and Amneal’s IPX203 (levodopa/carbidopa), which are delivered orally in a gastric-retentive capsule to prolong the absorption of levodopa. Conversely, AbbVie’s ABBV-951 (foslevodopa) and Mitsubishi’s ND-0612 (levodopa/carbidopa) are delivered subcutaneously using an external small pump that maintains a continuous and steady flow of levodopa throughout the day and night.
Elsayed adds: “These products are expected to create improved options for physicians to control complications that arise with the continued use of levodopa. Therefore, some of these products are set to gain strong market uptake. The most promising drug in this group is forecast to be AbbVie’s ABBV-951 with global sales of $673.8m by 2029.”
* 7MM: The US, France, Germany, Spain, Italy, the UK, and Japan.
- Overview of PD, including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and disease management.
- Annualized PD therapeutics market revenue, cost of therapy per patient, and treatment usage patterns in two patient segments (early and advanced) forecast from 2019 to 2029.
- Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping and implications for the PD therapeutics market
- Pipeline analysis: comprehensive data assessing emerging trends and mechanisms of action under development for PD therapy. The most promising candidates in Phase IIb and Phase III development are profiled.
- Analysis of the current and future market competition in the global PD therapeutics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.
Key Questions Answered
- What are the key PD treatments in 2019?
- When will the late stage pipeline products launch, and how will it affect drug sales and the overall PD market in the 7MM?
- Which unmet needs will remain unaddressed in the forecast period and what opportunities remain for pharmaceutical companies?
Current treatments for both early and advanced stage patients focus on controlling the level of dopamine in the brain.
GlobalData’s anticipate that 17 late stage pipeline drugs will launch over the forecast period. These will begin address longstanding unmet needs and are expected to be the main driver of growth in the PD market across the 7MM.
Roche/Prothena’s, a monoclonal antibody, has a novel MOA in the PD market and, if approved, will be revolutionary with potential neuroprotective properties.
The unmet need for therapies for treating late stage complications, such as wearing off, dyskinesia, and psychosis will remain unmet in the 5EU and Japan.
Opportunities are expected for pharmaceutical companies to develop drugs which have novel MOAs; which have potential disease modifying properties.
Reasons to buy
The report will enable you to:
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the global PD therapeutics market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global PD therapeutics market in the future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analysing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
Pharma Two B
Anavex Life Sciences
Living Cell Technologies
Table of Contents
| List of Tables
| List of Figures
| About GlobalData
1 Parkinson’s Disease: Executive Summary
1.1 Parkinson’s Market Expected to Grow Significantly, Driven by New Launches
1.2 High Opportunities and High Risks for Disease-Modifying Therapies Entering the PD Market
1.3 Diverse Pipeline Agents Will Partially Address Key Unmet Needs
1.4 The Entry of Novel Biologics and Innovative Delivery Systems Will Shape the PD Market
1.5 What Do Physicians Think?
2.2 Related Reports
2.3 Upcoming Reports
3 Disease Overview
3.1 Etiology and Pathophysiology
3.1.3 Mechanisms of Cell Death
3.2 Classification or Staging Systems
4.1 Disease Background
4.2 Risk Factors and Comorbidities
4.3 Global and Historical Trends
4.4 Forecast Methodology
4.4.2 Forecast Assumptions and Methods
4.5 Epidemiological Forecast for PD (2019-2029)
4.5.1 Diagnosed Prevalent Cases of PD
4.5.2 Sex-Specific Diagnosed Prevalent Cases of PD
4.5.3 Age-Specific Diagnosed Prevalent Cases of PD
4.5.4 Diagnosed Prevalent Cases of PD by HY Clinical Staging
4.5.5 Diagnosed Prevalent Cases of PD by Type
4.6.1 Epidemiological Forecast Insight
4.6.2 COVID-19 Impact
4.6.3 Limitations of Analysis
4.6.4 Strengths of Analysis
5 Disease Management
5.1 Diagnosis and Treatment Overview
5.2 KOL Insights on Disease Management
6 Competitive Assessment
7 Unmet Needs and Opportunity Assessment
7.2 Effective Treatment of Motor Complications – Dyskinesia, Off-Episodes, Gait, and Balance Problems
7.3 New Therapies for Non-motor Complications – Psychosis and Dementia
7.4 Neuroprotective/Disease-Modifying Agents
7.5 Improved Drug Formulations
8 R&D Strategies
8.1.1 Development of Novel Targets ─ mAbs Targeting α-synuclein, and Gene Therapies
8.1.2 Innovative Drug Delivery Systems
8.1.3 Secondary Indications and Drug Repurposing
8.1.4 Clinical Trial Design
8.1.5 Reliable Biomarkers of Disease Progression
8.1.6 Genetic Studies Required to Learn About Genetic Subtypes of PD
9 Pipeline Assessment
9.2 Promising Drugs in Clinical Development
10 Pipeline Valuation Analysis
10.2 Competitive Assessment
11 Current and Future Players
11.2 Deal-Making Trends
12 Market Outlook
12.1 Global Markets
12.1.2 Drivers and Barriers – Global Issues
12.2.2 Key Events
12.2.3 Drivers and Barriers
12.3.2 Key Events
12.3.3 Drivers and Barriers
12.4.2 Key Events
12.4.3 Drivers and Barriers
13.3.1 Forecasting Methodology
13.4 Primary Research – KOLs Interviewed for This Report
13.5 Primary Research – Prescriber Survey
13.6 About the Authors
13.6.2 Managing Analyst
13.6.3 Therapy Area Director
13.6.5 Managing Epidemiologist
13.6.6 Global Director of Therapy Analysis and Epidemiology
13.6.7 Global Head and EVP of Healthcare Operations and Strategy
| Contact Us
List of Tables
Table 1: Parkinson’s Disease: Key Metrics in the 7MM
Table 2: Modified HY Scale of PD Symptoms
Table 3: Movement Disorder Society-Sponsored Revision of the Unified PD Rating Scale (MDS-UPDRS), 2008
Table 4: Risk Factors and Comorbidities of PD
Table 5: Treatment Guidelines for PD
Table 6: Parkinson’s Disease Market – Global Drivers and Barriers, 2019-2029
Table 7: Key Events Impacting Sales for Parkinson’s Disease in the US, 2019-2029
Table 8: Parkinson’s Disease Market – Drivers and Barriers in the US, 2019-2029
Table 9: Key Events Impacting Sales for Parkinson’s Disease in the 5EU, 2019-2029
Table 10: Parkinson’s Disease Market – Drivers and Barriers in the 5EU, 2019-2029
Table 11: Key Events Impacting Sales for PD in Japan, 2019-2029
Table 12: PD Market – Drivers and Barriers in Japan, 2019-2029
Table 13: High-Prescribing Physicians (non-KOLs) Surveyed, By Country
List of Figures
Figure 1: Global Sales Forecast by Country for Parkinson’s Disease in 2019 and 2029
Figure 2: Analysis of the Company Portfolio Gap in Parkinson’s Disease During the Forecast Period
Figure 3: Competitive Assessment of the Late-Stage Pipeline Agents that GlobalData Expects to be Licensed for the Treatment of Parkinson’s Disease During the Forecast Period
Figure 4: 7MM, Diagnosed Prevalence (%) of PD, Both Sexes, Ages ≥18 Years, 2019
Figure 5: 7MM, Sources Used and Not Used to Forecast the Diagnosed Prevalent Cases of PD
Figure 6: 7MM, Sources Used to Forecast the Diagnosed Prevalent Cases of PD Segmented by HY Clinical Staging
Figure 7: 7MM, Diagnosed Prevalent Cases of PD, N, Both Sexes, Ages ≥18 Years, 2019
Figure 8: 7MM, Diagnosed Prevalent Cases of PD, N, by Sex, Ages ≥18 Years, 2019
Figure 9: 7MM, Diagnosed Prevalent Cases of PD by Age, N, Both Sexes, 2019
Figure 10: 7MM, Diagnosed Prevalent Cases of PD by HY Clinical Staging, N, Both Sexes, Ages ≥18 Years, 2019
Figure 11: 7MM, Diagnosed Prevalent Cases of PD by Type, N, Both Sexes, Ages ≥18 Years, 2019
Figure 12: Treatment Algorithm for Parkinson’s Patients
Figure 13: Unmet Needs and Opportunities in PD
Figure 14: Pharmacokinetics of Levodopa
Figure 15: Overview of the Development Pipeline in Parkinson’s Disease
Figure 16: Key Late-Stage Trials for the Promising Pipeline Agents that GlobalData Expects to Be Licensed for PD in the 7MM During the Forecast Period
Figure 17: Competitive Assessment of the Late-Stage Pipeline Agents that GlobalData Expects to Be Licensed for the Treatment of Parkinson’s Disease During the Forecast Period
Figure 18: Competitive Assessment of the Marketed and Pipeline Drugs Benchmarked Against the SOC, Sinemet
Figure 19: Competitive Assessment of the Marketed and Pipeline Drugs Benchmarked Against the SOC, Requip
Figure 20: Competitive Assessment of the Marketed and Pipeline Drugs Benchmarked Against the SOC, Nuplazid
Figure 21: Competitive Assessment of the Marketed and Pipeline Drugs Benchmarked Against the SOC, Azilect
Figure 22: Analysis of the Company Portfolio Gap in Parkinson’s Disease During the Forecast Period (2019-2029)
Figure 23: Global (7MM) Sales Forecast by Country for Parkinson’s Disease in 2019 and 2029
Figure 24: Sales Forecast by Class for Parkinson’s Disease in the US in 2019 and 2029
Figure 25: Sales Forecast by Class for Parkinson’s Disease in the 5EU in 2019 and 2029
Figure 26: Sales Forecast by Class for PD in Japan in 2019 and 2029